Similar companies
Income Statement (USD)
Q2 '25 | QoQ | |
---|---|---|
Operating expense | 212M | 4.5% |
Net Income | -198M | 10.6% |
EBITDA | -212M | 4.5% |
Balance Sheet (USD)
Q2 '25 | QoQ | |
---|---|---|
Total Assets | 550M | 19.9% |
Total Liabilities | 416M | 108.5% |
Total Equity | 135M | 48.1% |
Shares Outstanding | 102M | 0.4% |
Cash Flow (USD)
Q2 '25 | QoQ | |
---|---|---|
Cash from operations | -168M | 1.7% |
Cash from investing | -16M | 109.4% |
Cash from financing | 250M | 67604.6% |
EPS
Financial Highlights for Biohaven in Q2 '25
Operating Expenses for this period were 212M, showing a -4.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -198M, showing a 10.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -212M, showing a 4.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.